

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,002APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806180

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<i>OK</i>	AA	4,603,106	07/29/86	Cerami et al.	435	7	
<i>OK</i>	AB	4,822,776	04/18/89	Cerami et al.	514	21	
<i>OK</i>	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>OK</i>	AL	0212489A2	04.03.87	EPO	C07K	13/00	
<i>OK</i>	AM	0218868A2	22.04.87	EPO	C12P	21/02	
<i>OK</i>	AN	0288088A2	26.10.88	EPO	G01N	33/68	
<i>OK</i>	AO	0308378A2	22.03.89	EPO	C12N	15/00	
<i>OK</i>	AP	0380068A1	01.08.90	EPO	C12N	15/85	
<i>OK</i>	AO	0393438A3	24.10.90	EPO	C12N	15/12	X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>OK</i>	AR	Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," Nature, 316:552-554 (1985).
<i>OK</i>	AS	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science, 229:869-871 (1985).
<i>OK</i>	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," Science, 229:1202-1207 (1985).

EXAMINER

DATE CONSIDERED

Johnston 9/10/96
NLSBET

12/7/95

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,102APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806732

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
JS	AL2	0398327A1	22.11.90	EPO	C12P	21/02	
JS	AM2	0412486A1	13.02.91	EPO	C12P	21/08	
JS	AN2	0433900A1	26.06.91	EPO	C12N	15/12	
JS	AO2	0526905A2	10.02.93	EPO	C12N	15/12	
JS	AP2	WO91/02078	21.02.91	PCT	C12P	21/06	
JS	AQ2	WO92/07076	30.04.92	PCT	C12N	15/12	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JS	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986)
JS	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987)
JS	AW	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987)
JS	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987)
JS	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987)
JS	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987)
JS	AR2	Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987)
JS	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).

EXAMINER

JS *9/10/96*
NISDET

DATE CONSIDERED

12/7/95

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,102APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AL3	WO92/13095	06.08.92	PCT			
AM3	0260610A2	23.03.88	EPO	Clap 2/60		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988)
AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988)
AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, <i>Abstracts of Annual Meeting 1989</i>
AW2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989)
AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989)
AY2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989)
AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989)
AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989)

EXAMINER

John J. J. 9/10/96
NIBET

DATE CONSIDERED

12/7/95

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,102APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS


EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AS3	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990)
AT3	Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," <i>Abstract 3.25, Lymphoma Res.</i> 9:591 (1990)
AU3	Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990)
AV3	Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious diseases</i> , 161:1148-1152 (1990)
AW3	Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990)
AX3	Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990)
AY3	Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990)
AZ3	Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990)

EXAMINER

DATE CONSIDERED


 NISBET

12/7/95

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,102APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR4	Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990)
AS4	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990)
AT4	Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990)
AU4	Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990)
AV4	Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990)
AW4	Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990)
AX4	Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990)
AY4	Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990)

EXAMINER

DATE CONSIDERED

John J. ...
9/10/96
N/15/96

12/7/95

FORM PTO-1449
(REV. 7-80)ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,102INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Gunning Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>[initials]</i>	AZ4	Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991)
<i>[initials]</i>	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991)
	AS5	Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992)
<i>[initials]</i>	AT5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992)
<i>[initials]</i>	AU5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993)
<i>[initials]</i>	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993)
<i>[initials]</i>	AW5	Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985)
	AX5	Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985)

EXAMINER

DATE CONSIDERED

9/10/94
NIOBET

12/2/95

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,102APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AY5	Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990)
AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991)
AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991)

EXAMINER

DATE CONSIDERED

Johnson 9/10/94
N1602T

12/7/95

FORM PTO-1449
(REV. 7-80)ATTY. DOCKET NO.
NYU93-01MSERIAL NO.
08/192,102INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONAPPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED
AUG 16 1995
GROUP 1806

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AN3	91/09967	11.07.91	PCT			
	AO3	0351789A2	24.01.90	EPO			
	AP3	0350690A2	17.01.90	EPO			X
	AQ3	90/00902	08.02.90	PCT			
	AR3						
	AS3						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

9/10/96
NBBET

12/7/95